KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Operating Expenses (2016 - 2026)

Biogen has reported Operating Expenses over the past 18 years, most recently at $2.1 billion for Q1 2026.

  • For Q1 2026, Operating Expenses fell 0.93% year-over-year to $2.1 billion; the TTM value through Mar 2026 reached $8.3 billion, up 3.11%, while the annual FY2025 figure was $8.3 billion, 7.26% up from the prior year.
  • Operating Expenses for Q1 2026 was $2.1 billion at Biogen, down from $2.3 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $2.7 billion in Q3 2023 and troughed at $1.1 billion in Q3 2022.
  • A 5-year average of $2.0 billion and a median of $2.0 billion in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: crashed 54.28% in 2022 and later skyrocketed 134.88% in 2023.
  • Year by year, Operating Expenses stood at $1.9 billion in 2022, then rose by 7.96% to $2.1 billion in 2023, then rose by 3.27% to $2.2 billion in 2024, then grew by 7.96% to $2.3 billion in 2025, then dropped by 10.08% to $2.1 billion in 2026.
  • Business Quant data shows Operating Expenses for BIIB at $2.1 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.0 billion in Q3 2025.